Form 4: Enliven CMO Sells 45,000 Shares Under 10b5-1 Plan

Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised options and sold 45,000 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Summary

• Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics, Inc. (ELVN), engaged in transactions involving the company's common stock.
• On February 17, 2026, Collins exercised options to acquire 45,000 shares of common stock at an exercise price of $2.48 per share.
• Concurrently, Collins sold 45,000 shares of common stock at a weighted average price of $26.1747 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on October 19, 2025.
• Following these transactions, Collins beneficially owns 25,000 shares of common stock directly and 221,268 derivative securities (stock options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. While it's an insider sale, the pre-arranged 10b5-1 plan suggests it's for personal financial planning rather than a negative signal about the company's prospects.

Positives

• The option exercise indicates the insider realized a significant gain, with options exercised at $2.48 and shares sold at $26.1747.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting the sale was not based on new, non-public information.

Negatives

• The sale of 45,000 shares by a Chief Medical Officer could be perceived as a reduction in direct equity exposure, although it was pre-planned.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are common in the biotechnology and pharmaceutical sectors, especially when executives realize gains from vested options. The use of a 10b5-1 plan mitigates concerns that the sale is based on new, non-public information, aligning with standard executive compensation and liquidity management practices.

Related Party Transactions

• The exercise of stock options and subsequent sale of common stock by Helen Louise Collins, a Chief Medical Officer, constitutes a related party transaction as it involves an executive of the company.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could be interpreted in various ways, but the 10b5-1 plan suggests it is not a signal of lack of confidence. It represents a slight reduction in direct insider ownership.

Key Dates

Recommendation

The insider sale by the Chief Medical Officer, while a reduction in direct equity, was executed under a pre-arranged 10b5-1 plan. This suggests the transaction is for personal financial management rather than a reflection of new negative company-specific information. Therefore, it does not warrant a change in investment thesis based solely on this filing, leading to a 'hold' recommendation.

Keywords

Enliven Therapeutics, ELVN, Form 4, Insider Trading, Stock Sale, Option Exercise, Helen Louise Collins, Chief Medical Officer, 10b5-1 Plan, Biotechnology, Pharmaceuticals